Linnaeus Therapeutics scientific cofounders publish preclinical pancreatic cancer data in cellular and molecular gastroenterology and hepatology

Linnaeus Therapeutics, a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, announced that its scientific cofounders, Christopher Natale, PhD, Vice President of Research at Linnaeus and Todd Ridky, MD, PhD, Assistant Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania, presented their findings on a new therapeutic target for pancreatic cancer in the journal Cellular and Molecular Gastroenterology and Hepatology.

Read more on the PR Newswire

Skip to content